Luye Pharma Group Ltd (2186) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Luye Pharma Group Ltd (2186) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH222570D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group's products include paclitaxel liposome, lentinan, sodium glycididazole, arsenious acid, and xuezhikang, among others. It also provides amifostine, oxaliplatin, meloxicam, pioglitazone hydrochloride, reduced glutathione, and selegiline hydrochloride, among others. Luye Pharma Group's products are used in therapeutic areas including endocrinology, oncology, cardiovascular, orthopedics, gastroenterology, hepatology, gynecology, and central nervous system, among others. The group offers its products through its distributors located across China. Luye Pharma Group is headquartered in Yantai, China.

Luye Pharma Group Ltd (2186)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Shandong Luye Pharma Acquires LY01008 and LY06006 from Shandong Boan Biological Technology for USD67 Million 12

Private Equity 13

CDH Investments, CITIC Private Equity and New Horizon Acquires Majority Stake in Luye Pharma 13

Partnerships 14

Luye Pharma Enters into Partnership with Elpis Biopharma 14

Licensing Agreements 15

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 15

Abpro Enters into Licensing Agreement with Luye Pharma 16

Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 17

Excel BioPharma Enters into Licensing Agreement with Luye Pharma 18

Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 19

Equity Offering 20

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 20

Luye Pharma Completes IPO 21

Debt Offering 23

Luye Pharma Plans to Raise up to USD302.6 Million in Public Offering of Notes 23

Acquisition 24

Luye Group May Acquire Ethypharm from Astorg Partners 24

A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For USD 4.8 Million 25

Luye Pharma Group Ltd-Key Competitors 26

Luye Pharma Group Ltd-Key Employees 27

Luye Pharma Group Ltd-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 31

Financial Announcements 31

Mar 26, 2018: Luye Pharma Group: Annual Results Announcement For The Year Ended 31 December 2017 31

Aug 28, 2017: Luye Pharma Group: Announcement Of Interim Results For The Six Months Ended 30 June 2017 36

Mar 29, 2017: Luye Pharma Group: Annual Results Announcement For The Year Ended 31 December 2016 41

Clinical Trials 42

Jun 19, 2018: Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials 42

Other Significant Developments 43

May 27, 2017: Investors flock to exicure s IPO-Luye Pharma s strategy of investment in novel biopharmaceuticals receives optimistic outlook 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Luye Pharma Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Shandong Luye Pharma Acquires LY01008 and LY06006 from Shandong Boan Biological Technology for USD67 Million 12

CDH Investments, CITIC Private Equity and New Horizon Acquires Majority Stake in Luye Pharma 13

Luye Pharma Enters into Partnership with Elpis Biopharma 14

Luye Pharma and Luye Supply to Enter into Agreement with Bayer 15

Abpro Enters into Licensing Agreement with Luye Pharma 16

Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 17

Excel BioPharma Enters into Licensing Agreement with Luye Pharma 18

Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 19

Exicure Raises Additional USD11.2 Million in Private Placement of Shares 20

Luye Pharma Completes IPO 21

Luye Pharma Plans to Raise up to USD302.6 Million in Public Offering of Notes 23

Luye Group May Acquire Ethypharm from Astorg Partners 24

A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For USD 4.8 Million 25

Luye Pharma Group Ltd, Key Competitors 26

Luye Pharma Group Ltd, Key Employees 27

Luye Pharma Group Ltd, Other Locations 28

Luye Pharma Group Ltd, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Luye Pharma Group Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17250
Site License
USD 500 INR 34500
Corporate User License
USD 750 INR 51750

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com